Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4231 to 4245 of 8906 results

  1. How we develop HealthTech guidance

    Our Medical Technologies Evaluation Programme (MTEP) evaluates new HealthTech.

  2. Get involved with HealthTech guidance

    We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.

  3. How we support healthtech commissioning

    Home What NICE does Our guidance About HealthTech guidance NICE: backing the healthtech that changes lives {"@context":"http://schema.org","@ty

  4. How we support healthtech developers

    With around 2 million healthtech products registered for UK use, differentiating your innovation from the competition is vital. A NICE recommendation helps you cut through the noise, demonstrate your product’s value and smooth your path to market.

  5. News Articles

    Home News Articles {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/"

  6. NICE: backing the healthtech that changes lives

    Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.

  7. Guidance, NICE advice and quality standards in development

    View a complete list of all our guidance, NICE advice and quality standards currently in development

  8. Topic prioritisation

    Find out what guidance is being considered for development

  9. Guidance and quality standards awaiting development

    Find out which guidance and quality standards are awaiting development

  10. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (HTG714)

    Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.

  11. Guidance and quality standards in consultation

    See a complete list of all our guidance and quality standards currently open for consultation

  12. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

  13. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (HTG316)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.

  14. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.